Studies on glucocorticoids in sports drug testing
- Autores: Sergi Coll Camenforte
- Directores de la Tesis: Rosa Ventura Alemany (dir. tes.)
- Lectura: En la Universitat Pompeu Fabra ( España ) en 2019
- Idioma: español
- Tribunal Calificador de la Tesis: Irene Mazzoni (presid.), Xavier de la Torre Fornell (secret.), Francisco Drobnic Martínez (voc.)
- Programa de doctorado: Programa de Doctorado en Biomedicina por la Universidad Pompeu Fabra
- Materias:
- Texto completo no disponible (Saber más ...)
- Resumen
Due to health risks associated to the use of glucocorticoids (GC) and their potential ergogenic effects, systemic GCs are prohibited in sports competitions. However, local GC administrations are allowed for therapeutic purposes. The general reporting level used nowadays to discriminate between prohibited and allowed administrations is not adequate for all GCs.
To improve the discrimination, the excretion profiles of different GCs (triamcinolone hexacetonide, triamcinolone acetonide, budesonide and betamethasone) were evaluated after prohibited and allowed administrations, and specific discrimination criteria were proposed for each GC. The urinary elimination times of systemic GCs were also evaluated. Moreover, local intra-articular administration of GCs was demonstrated to produce systemic effect.
Finally, the impact of GCs on the steroid profile was evaluated. Due to the inhibition of the hypothalamic-pituitary-adrenal axis, the excretion rates of steroid profile metabolites decreased after systemic GC use. Nonetheless, the ratios between metabolites were not affected. Thus, GC administration does not affect the steroid profile.
